Annals of Surgical Oncology

, Volume 21, Issue 3, pp 1010–1015

Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?

  • Liang-He Yu
  • Nan Li
  • Jie Shi
  • Wei-Xing Guo
  • Meng-Chao Wu
  • Shu-Qun Cheng
Hepatobiliary Tumors

DOI: 10.1245/s10434-013-3320-z

Cite this article as:
Yu, LH., Li, N., Shi, J. et al. Ann Surg Oncol (2014) 21: 1010. doi:10.1245/s10434-013-3320-z

Abstract

The Hepatitis B virus (HBV) is an important etiological factor for hepatocarcinogenesis, because HBV DNA load and HBV reactivation are major risks that influence the long-term survival of hepatocellular carcinoma (HCC) patients who underwent hepatectomy and, thus, may cause postoperative liver function deterioration, tumor recurrence, and reduce patient’s overall survival. However, anti-HBV therapy can suppress HBV replication, improve the remnant liver function, render patients better able to tolerate HCC treatments, and may even improve their prognosis. In this paper, an anti-HBV therapy that benefits the prognosis of HBV-related HCC following hepatectomy is reviewed.

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Liang-He Yu
    • 1
  • Nan Li
    • 1
  • Jie Shi
    • 1
  • Wei-Xing Guo
    • 1
  • Meng-Chao Wu
    • 1
  • Shu-Qun Cheng
    • 1
  1. 1.Eastern Hepatobiliary Surgery HospitalThe Second Military Medical UniversityShanghaiChina

Personalised recommendations